Inactive

SOURCES SOUGHT NOTICE Solicitation Number: 75N95022Q00517 Title: Reagent Injector Module (Part number: 1100-472-702) Brand name or equal Classification Code: 6640 - LABORATORY EQUIPMENT AND SUPPLIES N... SOURCES SOUGHT NOTICE Solicitation Number: 75N95022Q00517 Title: Reagent Injector Module (Part number: 1100-472-702) Brand name or equal Classification Code: 6640 - LABORATORY EQUIPMENT AND SUPPLIES NAICS Code: 334516, Analytical Laboratory Instrument Manufacturing Size Standard: 1,000 Employees Description: The purpose of this requisition is to procure and install a Reagent Injector Module (Part Number: 1100-472-702) in the Pherastar FSX microplate reader, for the Therapeutic Development Branch (TBD) within the National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) in order to allow allow TBD scientists to run high-throughput screening with different drug libraries to find therapy for Deficiency of N-glycanase 1 (NGLY1) disorder. NCATS currently owns a Pherastar FSX microplate reader with no reagent injector module. The injector module on the Pherastar FSX microplate reader will be used for performing a particular cell based assay for the NGLY1 project. The signal from this cell based assay is stable only for one (1) to two (2) minutes. This short period of time precludes the performance of high-throughput screening with the Pherastar FSX assay system. The injector module will allow TBD scientists to add the reagents to each well and read the signal right away using the Pherastar FSX microplate reader. This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. For equipment/supply requirements, small business responses must include: (1) the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture), as well as (2) the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule). Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Division of Preclinical Innovation (DPI) plans, conducts and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum. Specifically, this division: • Plans, conducts and collaborates on research to develop new methods and technologies to enhance preclinical processes. • Plans, conducts and collaborates on research to evaluate existing and developing approaches, technologies, and processes in the preclinical spectrum. • Supports training programs relevant to preclinical phases of translational science. • Allocates DPI resources to preclinical extramural and intramural investigators. • Collaborates with other NIH Institutes and Centers and the scientists they support. • Consults with stakeholders, including patients, industry and regulators Several thousand genetic diseases affect humans, of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. Within NCATS, the TDB biology group works to encourage and speed the development of new treatments for diseases with high-unmet medical needs. This acquisition specifically addresses the new therapeutic for NGLY1 rare disease project, which specifically applies breakthroughs in translational science to advancing new treatments for rare diseases. Thus, the Therapeutic Development Branch (TBD) within the National Center for Advancing Translational Sciences (NCATS) Division of Preclinical Innovation (DPI) requires the acquisition and installation of the Reagent Injector Module (Part Number: 1100-472-702) on the Pherastar FSX microplate reader to allow allow TBD scientists to run high-throughput screening with different drug libraries to find therapy for Deficiency of N-glycanase 1 (NGLY1) disorder. Project requirements: One (1) Reagent Injector Module (Part number: 1100-472-702) with installation in the Pherastar FSX microplate reader already installed at NCATS. Quantity Part Number Product Brand Name Manufacturer 1 Ea 1100-472-702 Reagent Injector Module BMG Labtech Salient characteristics At a minimum, the salient physical, functional, or performance characteristics that equal” products must meet are as follows: •Two Internal syringe injectors that dispense 5 to 350 uL in 0.167 uL increments; •Low 0.5ml prime volume; •Software shall allow individually defined volumes for each well; •Fully compatible with the Pherastar FSX microplate reader (Serial Number: 902-0484); •Installation on-site; and •Handling and Shipping, FOB Destination. Anticipated period of performance: The Contractor shall deliver the equipment described above within 30 days after receipt of order (ARO). The equipment shall be delivered to the NCATS, 9800 Medical Center Drive, Rockville, MD 20850 between the hours of 8:00 am and 5:00 pm, Eastern Daylight Time, Monday through Friday (except federal holidays). Delivery shall be Freight on Board (FOB) destination and shall include inside delivery. Capability statement /information sought. Small business concerns that believe they possess the capabilities to provide the required products should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Small businesses must also provide their Company Name, DUNS number, Physical Address, and Point of Contact Information. Interested small businesses are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Nick Niefeld, Contract Specialist at e-mail address nick.niefeld@nih.gov. The response must be received on or before August 25, 2022 at 9 AM, Eastern Time. “Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).”